This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Michael Sela | |
|---|---|
| Name | Michael Sela |
| Birth date | 2 March 1924 |
| Birth place | Ostrołęka |
| Death date | 27 May 2022 |
| Death place | Rehovot |
| Nationality | Israel |
| Fields | Immunology |
| Alma mater | Hebrew University of Jerusalem, Weizmann Institute of Science |
| Known for | Development of synthetic antigens, research on autoimmune diseases, development of copolymer 1 |
| Awards | Israel Prize, EMET Prize, Fellow of the Royal Society |
Michael Sela was an Israeli immunologist and molecular immunology pioneer whose work on synthetic antigens and peptide chemistry transformed understanding of adaptive immunity and autoimmune disease. He was a long-serving leader at the Weizmann Institute of Science, where he developed immunochemical methods that informed vaccine design and immunotherapy. His career bridged basic research, translational science, and institutional leadership.
Born in Ostrołęka, then part of the Second Polish Republic, he emigrated to British Mandate of Palestine as a youth, joining a community shaped by Zionist movement migrations and the upheavals of World War II. He studied at the Hebrew University of Jerusalem and completed advanced research training at the Weizmann Institute of Science, where he worked with leading figures in biochemistry and immunology research. His formative years intersected with major 20th-century scientific and political developments including interactions with scholars from Cambridge, Harvard University, and ties to laboratories influenced by the legacy of Paul Ehrlich and Karl Landsteiner.
He established a laboratory at the Weizmann Institute of Science that became a center for research in immunology and peptide chemistry, attracting collaborators from institutions such as Columbia University, Stanford University, and Rockefeller University. Over decades he supervised many students who later joined faculties at Massachusetts Institute of Technology, University of Oxford, University of California, San Francisco, and Tel Aviv University. He engaged in collaborative projects with industrial partners in Switzerland and United States biotechnology sectors, participating in conferences of the International Union of Immunological Societies and symposia organized by the Royal Society.
He pioneered the synthesis and use of defined synthetic antigens and polypeptides to map immune recognition, building on conceptual foundations from Jules Bordet and Niels Jerne. His laboratory developed methods for analyzing antigenic determinants and T cell recognition that informed the design of the copolymer known as Copaxone (glatiramer acetate), which became a therapy for multiple sclerosis. He contributed to elucidating mechanisms of autoimmunity, tolerance, and the role of major histocompatibility complex interactions akin to findings associated with Peter Doherty and Rolf Zinkernagel. His work connected to research on cytokine signaling pathways described by scientists like Charles Dinarello and Shizuo Akira, and to concepts advanced by Emil von Behring and Élie Metchnikoff regarding humoral and cellular immunity. He published influential papers that intersected with studies from National Institutes of Health, European Molecular Biology Laboratory, and groups at Johns Hopkins University.
He received major recognitions including the Israel Prize in life sciences and the EMET Prize for lifetime achievement. He was elected a foreign member or fellow of bodies such as the Royal Society and held honorary degrees from universities including University of Cambridge and Hebrew University of Jerusalem. His awards paralleled honors given to contemporaries like Baruj Benacerraf, Niels Jerne, and Susumu Tonegawa for contributions to immunology and medicine.
He served as president of the Weizmann Institute of Science and chaired scientific councils and prize committees including roles in the Israel Academy of Sciences and Humanities and philanthropic advisory boards connected to institutions like the Gordon Foundation and European Research Council-aligned initiatives. He participated in national science policy, interfacing with ministries and research funding bodies such as the Israel Ministry of Science and Technology and international organizations including the World Health Organization and European Molecular Biology Organization.
He was part of a family connected to Israeli scientific and cultural circles, maintaining ties to colleagues at Technion – Israel Institute of Technology and participating in public discussions featuring figures from Knesset committees and cultural institutions like the Israel Museum. His personal correspondences and archived papers were consulted by historians studying postwar science migration and the development of Israeli research institutions influenced by networks including Weizmann Institute of Science founders and advisors from Zionist Organization contexts.
His legacy includes the translational pathway from basic peptide chemistry to an approved therapeutic for multiple sclerosis, shaping practices in immunotherapy, vaccine antigen design, and autoimmunity research alongside contemporaries at NIH and leading European laboratories. The generation of scientists he trained populated faculties at Columbia University, Yale University, University of Toronto, and major Israeli universities, continuing work in areas related to cancer immunotherapy, infectious disease immunology, and structural immunology. Institutional initiatives and prizes he helped establish continue to influence funding and recognition for biomedical research in Israel and internationally.
Category:Israeli immunologists Category:Weizmann Institute of Science people